TopoTarget Receives Broad US and EU Patents for Key HDAC Inhibitors
The US patent covers a family of Sulphonamide HDAC inhibitors including PXD101, the oncology therapy which TopoTarget is co-developing with CuraGen Corporation for the treatment of solid and haematologic cancers and which is currently in Phase II clinical trials for the treatment of multiple myeloma. The patent covers the use of TopoTarget sulphonamides in the treatment of cancer and other diseases where the inhibition of HDAC enzymes would be of benefit.
The European patent, which covers 20 European countries, covers the use of valproic acid and derivatives as HDAC inhibitors in the treatment of solid tumours. The patent is relevant to two TopoTarget oncology therapies based on valproic acid which are scheduled to enter Phase II clinical trials later this year: BACECA® for non-melanoma skin cancers and PEAC® as a suppression therapy in patients with a genetic predisposition to develop colon cancer, an indication for which PEAC® was granted Orphan Medicinal Product Designation in Europe in 2004.
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.